Patients with squamous cell carcinoma of the head and neck were randomly assigned to receive either intensity-modulated radiotherapy with weekly cetuximab or radiotherapy alone.

The Au-HN-1 nanosystem represents a breakthrough in TSCC treatment, integrating targeted photothermal therapy with advanced ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and ...

Bristow's report suggests that the current share price does not account for the potential success of subsequent programs, including those for head and neck squamous cell carcinoma (HNSCC), ...

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BCAX stock, giving a Buy rating on January 22.Invest with ...

McDermott says that he started seeing a dermatologist when he was in his 20s at the recommendation of his parents.

Rakuten Medical initiates global phase 3 trial of ASP-1929 photoimmunotherapy in combo with pembrolizumab to treat recurrent head and neck cancer: United States Saturday, January ...

TWO women lose their lives to cervical cancer every day in the UK. Like all types of the disease, the earlier it’s caught, the better. Around 95 per cent of those diagnosed at stage 1 will ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...